Detalles de la búsqueda
1.
Phase I Trial of a Tablet Formulation of Pilaralisib, a Pan-Class I PI3K Inhibitor, in Patients with Advanced Solid Tumors.
Oncologist;
23(4): 401-e38, 2018 04.
Artículo
en Inglés
| MEDLINE | ID: mdl-29593099
2.
A phase I dose-escalation study of the safety and pharmacokinetics of a tablet formulation of voxtalisib, a phosphoinositide 3-kinase inhibitor, in patients with solid tumors.
Invest New Drugs;
36(1): 36-44, 2018 02.
Artículo
en Inglés
| MEDLINE | ID: mdl-28417284
3.
Phase I Dose-Escalation Study of Pilaralisib (SAR245408, XL147) in Combination with Paclitaxel and Carboplatin in Patients with Solid Tumors.
Oncologist;
22(4): 377-e37, 2017 04.
Artículo
en Inglés
| MEDLINE | ID: mdl-28275119
4.
Phase Ib trial of the PI3K/mTOR inhibitor voxtalisib (SAR245409) in combination with chemoimmunotherapy in patients with relapsed or refractory B-cell malignancies.
Br J Haematol;
175(1): 55-65, 2016 Oct.
Artículo
en Inglés
| MEDLINE | ID: mdl-27293194
5.
Phase I dose-escalation study of pilaralisib (SAR245408, XL147), a pan-class I PI3K inhibitor, in combination with erlotinib in patients with solid tumors.
Oncologist;
20(3): 245-6, 2015 Mar.
Artículo
en Inglés
| MEDLINE | ID: mdl-25669662
6.
Local delivery of mRNA-encoded cytokines promotes antitumor immunity and tumor eradication across multiple preclinical tumor models.
Sci Transl Med;
13(610): eabc7804, 2021 Sep 08.
Artículo
en Inglés
| MEDLINE | ID: mdl-34516826
7.
Phase I study of pazopanib in combination with weekly paclitaxel in patients with advanced solid tumors.
Oncologist;
15(12): 1253-61, 2010.
Artículo
en Inglés
| MEDLINE | ID: mdl-21147873
8.
A Phase II, open-label study evaluating pazopanib in patients with recurrent ovarian cancer.
Gynecol Oncol;
119(1): 32-7, 2010 Oct.
Artículo
en Inglés
| MEDLINE | ID: mdl-20584542
9.
Voxtalisib (XL765) in patients with relapsed or refractory non-Hodgkin lymphoma or chronic lymphocytic leukaemia: an open-label, phase 2 trial.
Lancet Haematol;
5(4): e170-e180, 2018 Apr.
Artículo
en Inglés
| MEDLINE | ID: mdl-29550382
10.
Phase Ib Study of Safety and Pharmacokinetics of the PI3K Inhibitor SAR245408 with the HER3-Neutralizing Human Antibody SAR256212 in Patients with Solid Tumors.
Clin Cancer Res;
23(14): 3520-3528, 2017 Jul 15.
Artículo
en Inglés
| MEDLINE | ID: mdl-28031425
11.
Janus kinase-2 inhibitor fedratinib in patients with myelofibrosis previously treated with ruxolitinib (JAKARTA-2): a single-arm, open-label, non-randomised, phase 2, multicentre study.
Lancet Haematol;
4(7): e317-e324, 2017 Jul.
Artículo
en Inglés
| MEDLINE | ID: mdl-28602585
12.
Phase I Trial of the Pan-PI3K Inhibitor Pilaralisib (SAR245408/XL147) in Patients with Chronic Lymphocytic Leukemia (CLL) or Relapsed/Refractory Lymphoma.
Clin Cancer Res;
21(14): 3160-9, 2015 Jul 15.
Artículo
en Inglés
| MEDLINE | ID: mdl-25840972
13.
Phase I dose-escalation study of the PI3K/mTOR inhibitor voxtalisib (SAR245409, XL765) plus temozolomide with or without radiotherapy in patients with high-grade glioma.
Neuro Oncol;
17(9): 1275-83, 2015 Sep.
Artículo
en Inglés
| MEDLINE | ID: mdl-26019185
14.
A phase I study of bevacizumab (B) in combination with everolimus (E) and erlotinib (E) in advanced cancer (BEE).
Cancer Chemother Pharmacol;
67(2): 465-74, 2011 Feb.
Artículo
en Inglés
| MEDLINE | ID: mdl-21079958
15.
Pooled analysis of phase II window studies in children with contemporary high-risk metastatic rhabdomyosarcoma: a report from the Soft Tissue Sarcoma Committee of the Children's Oncology Group.
J Clin Oncol;
24(21): 3415-22, 2006 Jul 20.
Artículo
en Inglés
| MEDLINE | ID: mdl-16849756
Resultados
1 -
15
de 15
1
Próxima >
>>